Medien
News & Pressemitteilungen
Filtern nach
Analog Pharma und Dipharma geben die Genehmigung der US FDA für einen abgekürzten Antrag auf ein neues Medikament (ANDA) für 20 mg generische Nitisinon-Kapseln (Temperaturstabil) bekannt.
Princeton, NJ and Chiasso, Switzerland, May 31st, 2023 | Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) is pleased to announce that their 20 mg nitisinone abbreviated new drug applicatio...
Dipharma SA wird als eines der besten Unternehmen der Schweiz für 2022 ausgezeichnet
Chiasso, September 15th, 2022 | Dipharma SA, a specialty pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized as one of the best places to work for in Switzerland. During the ass...
Nachrichten
Besuchen Sie unseren Stand im Rahmen der APS in Kassel
Visit us at our booth at the APS from 19.10.-21.10.2022 in Kassel, Germany, we are looking forward to meet you there.
Press
Analog Pharma und Dipharma geben die Genehmigung der US FDA für einen abgekürzten Antrag auf ein neues Medikament (ANDA) für generische Nitisinon-Kapseln (temperaturstabil) bekannt
Rosemont, PA and Chiasso, Switzerland, June 21st, 2022 – Analog Pharma (“Analog”) and Dipharma S.A. (“Dipharma”) today announced that their nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug ...
Nachrichten
Interview mit PharmaBoardRoom
Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen the largely unexplored rare diseases generics space and the opportunities in metabolic diseases. Marc-Olivier Geinoz – CEO, Dipharma SA Dipharma SA is a Swiss specialty pha...
Miglustat Dipharma ist jetzt in der Schweiz erhältlich
Chiasso, Switzerland, February 16th, 2021 – Swiss-based Dipharma S.A. (“Dipharma”) today announced that its proprietary product Miglustat Dipharma 100 mg capsules is now available in Switzerland. Miglustat Dipharma, a generic equivalent to Actelio...
Dipharma SA gibt bekannt, dass die FDA den Antrag auf das abgekürzte Zulassungsverfahren (ANDA) für das generische Nitisinon zur Prüfung angenommen hat.
Chiasso, Switzerland, January 24th, 2019 – Dipharma S.A. (“Dipharma”) today announced that the U.S. Food and Drug Administration (FDA) accepted its nitisinone abbreviated new drug application (ANDA) for review. Nitisinone is a generic equivalent t...
Press
Dipharma SA gibt die Erteilung der zentralen Marktzulassung für das generische Miglustat in Europa bekannt
Chiasso, Switzerland, February 20th, 2019 – – Dipharma S.A. (“Dipharma”) today announced that the European Commission has granted Marketing Authorization of its generic Miglustat. This authorization comes after CHMP positive opinion last December ...
Amerigen und Dipharma SA geben die Zulassung durch die U. S. FDA für das generische Miglustat 100 mg Kapseln bekannt.
The first generic version of Miglustat is now approved in the U.S. Lyndhurst, N.J. and Chiasso, Switzerland. April 18th, 2018 – Amerigen Pharmaceuticals Limited (“Amerigen”) and Dipharma S.A. (“Dipharma”) today announced that Amerigen’s Abbr...
Dipharma SA gibt die Validierung des Antrags auf Marktzulassung von Disanit® (Nitisinon) in Europa bekannt.
The first stable capsule formulation of Nitisinone for the treatment of hereditary Tyrosinemia type-1 (HT-1) is now under marketing authorization (MA) evaluation in the EU. Chiasso, Switzerland, February 23rd, 2017 – Dipharma S.A. announces the va...
